<p>隨着全球市場應對貿易政策的複雜性和波動的通貨膨脹率，美國股市展現出韌性，主要指數顯著上漲，儘管在週末出現了一些拋售壓力。在這種環境下，內部持股比例高的成長型公司因其管理層與股東之間的利益一致性而顯得尤為突出，這在持續的經濟不確定性中可能帶來特別的優勢。</p>
<h3>全球內部持股比例高的十大成長型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>上海華測導航技術（深交所：300627）</td>
<td>24.5%</td>
<td>23.4%</td>
</tr>
<tr>
<td>富林精密（深交所：300432）</td>
<td>13.6%</td>
<td>44.2%</td>
</tr>
<tr>
<td>KebNi（OM:KEBNI B）</td>
<td>38.3%</td>
<td>67%</td>
</tr>
<tr>
<td>Pharma Mar（BME:PHM）</td>
<td>11.8%</td>
<td>43.1%</td>
</tr>
<tr>
<td>老普金（港交所：6181）</td>
<td>35.5%</td>
<td>40.6%</td>
</tr>
<tr>
<td>浙江零跑科技（港交所：9863）</td>
<td>15.6%</td>
<td>60.1%</td>
</tr>
<tr>
<td>Vuno（KOSDAQ:A338220）</td>
<td>15.6%</td>
<td>109.8%</td>
</tr>
<tr>
<td>蘇州三門科技（深交所：300522）</td>
<td>35.4%</td>
<td>77.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories（OB:ELABS）</td>
<td>22.9%</td>
<td>79%</td>
</tr>
<tr>
<td>Techwing（KOSDAQ:A089030）</td>
<td>18.8%</td>
<td>68%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們內部持股比例高的 840 只快速成長全球公司的完整名單。</p>
<p>在這裏，我們重點介紹我們獨家篩選器中的幾家最愛。</p>
<h2>3Peak（上交所：688536）</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 3Peak Incorporated 專注於模擬集成電路產品的研發和銷售，業務覆蓋中國及國際市場，市值為 190.6 億人民幣。</p>
<p><strong>運營：</strong> 公司在集成電路行業的運營收入為 14.4 億人民幣。</p>
<p><strong>內部持股比例：</strong> 14.2%</p>
<p><strong>收入增長預測：</strong> 年均 26.6%。</p>
<p>3Peak 的收入預計將顯著增長，年均增長 26.6%，超過中國市場的平均增長率。公司最近報告了扭虧為盈，2025 年第一季度淨收入為 1556 萬人民幣，而去年則出現虧損。儘管其股價波動性較高，且預計股本回報率較低，但預計將在三年內實現盈利，反映出在穩定的內部持股動態下強勁的增長潛力。</p>
<ul>
<li>通過閲讀我們的分析師估計報告，深入瞭解 3Peak 的表現。</li>
<li>我們的估值報告揭示了 3Peak 的股票可能以溢價交易的可能性。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4f33f209-075c-4e96-ac20-46f7ba1204f6/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4f33f209-075c-4e96-ac20-46f7ba1204f6/chart/earnings-and-revenue-growth"/></p>
<p>上交所：688536 截至 2025 年 6 月的收益和收入增長</p>
<h2>奇安信科技集團（上交所：688561）</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 奇安信科技集團有限公司是一家網絡安全公司，向中國及國際的政府、企業和其他機構提供產品和服務，市值為 205.8 億人民幣。</p>
<p><strong>運營：</strong> 公司在信息安全行業的收入為 43.3 億人民幣。</p>
<p><strong>內部持股比例：</strong> 22%</p>
<p><strong>收入增長預測：</strong> 年均 19.3%。</p>
<p>奇安信科技集團有望實現增長，預計收入年均增長 19.3%，超過中國市場的平均水平。儘管 2025 年第一季度淨虧損為 4.1768 億人民幣，但預計公司將在三年內實現盈利，顯示出強勁的增長潛力。其股票以顯著折扣交易於估計公允價值，並且最近宣佈了一項 3 億人民幣的私募配售，待股東批准，這表明在穩定的內部持股下進行戰略財務操作。</p>
<ul>
<li>點擊這裏瞭解奇安信科技集團的細微差別，查看我們的詳細分析未來增長報告。</li>
<li>根據我們最近的估值報告，奇安信科技集團的股票似乎低於其估計價值。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aabf5e41-e45f-4e0e-b547-15bab0c91da9/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aabf5e41-e45f-4e0e-b547-15bab0c91da9/chart/ownership-breakdown"/></p>
<p>上交所：688561 截至 2025 年 6 月的持股結構</p>
<h2>浙江佐力藥業（深交所：300181）</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 浙江佐力藥業有限公司從事中藥產品的研發、生產和營銷，業務覆蓋國內外，市值為 111.1 億人民幣。</p>
<p><strong>運營：</strong> 浙江佐力藥業有限公司主要通過中藥產品的研發、生產和營銷在國內外市場產生收入。</p>
<p><strong>內部持股比例：</strong> 23.1%</p>
<p><strong>收入增長預測：</strong> 年均 20.4%。</p>
<p>浙江佐力藥業顯示出良好的增長前景，預計收入年均增長 20.4%，超過中國市場。儘管其 3.38% 的股息收益率未完全由自由現金流覆蓋，但與同行相比，該公司以良好的價值交易，且價格顯著低於其估計公允價值。最近的財報顯示出強勁的財務表現，銷售和淨收入同比增長，而內部持股保持穩定，近期沒有重大交易活動。</p>
<ul>
<li>點擊以探索我們在浙江佐力藥業收益增長報告中的詳細發現。</li>
<li>我們的浙江佐力藥業估值報告中的分析暗示其股價相較於估計價值被低估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/622eb9bb-56e4-4333-9ef3-063c670c87d3/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/622eb9bb-56e4-4333-9ef3-063c670c87d3/chart/earnings-and-revenue-growth"/></p>
<p>深交所：300181 截至 2025 年 6 月的收益和收入增長</p>
<h2>接下來該如何？</h2>
<ul>
<li>點擊這裏訪問我們 840 家快速成長全球公司內部持股比例高的完整索引。</li>
<li>尋找其他投資？發現 19 家在 COVID 後生存並蓬勃發展的公司，具備應對特朗普關税的正確條件。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不意圖提供財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有引用的預測收入和盈利增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>

佐力藥業

<p>在 2025 年 6 月，美國股市在貿易政策複雜性和通貨膨脹波動中表現出韌性，高內部持股的成長型公司成為強有力的投資選擇。值得注意的公司包括 3Peak、奇安信科技集團和浙江佐力藥業，這些公司都展現出顯著的收入增長預測和穩定的內部持股。儘管其中一些公司面臨淨虧損，但預計在三年內將實現盈利，顯示出強勁的增長潛力。文章強調了管理層與股東之間利益的一致性作為在不確定經濟條件下的關鍵優勢</p>

<p>As global markets navigate the complexities of trade policies and fluctuating inflation rates, U.S. stocks have shown resilience with notable gains in major indices, despite some late-week selling pressures. In this environment, growth companies with high insider ownership stand out as potentially robust investments due to their alignment of interests between management and shareholders, which can be especially advantageous amidst ongoing economic uncertainties.</p>
<div class="lb-trans"><p>隨着全球市場應對貿易政策的複雜性和波動的通貨膨脹率，美國股市展現出韌性，主要指數顯著上漲，儘管在週末出現了一些拋售壓力。在這種環境下，內部持股比例高的成長型公司因其管理層與股東之間的利益一致性而顯得尤為突出，這在持續的經濟不確定性中可能帶來特別的優勢。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership Globally</h3>
<div class="lb-trans"><h3>全球內部持股比例高的十大成長型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Shanghai Huace Navigation Technology (SZSE:300627)</td>
<td>24.5%</td>
<td>23.4%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>13.6%</td>
<td>44.2%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38.3%</td>
<td>67%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.8%</td>
<td>43.1%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>40.6%</td>
</tr>
<tr>
<td>Zhejiang Leapmotor Technology (SEHK:9863)</td>
<td>15.6%</td>
<td>60.1%</td>
</tr>
<tr>
<td>Vuno (KOSDAQ:A338220)</td>
<td>15.6%</td>
<td>109.8%</td>
</tr>
<tr>
<td>Suzhou Sunmun Technology (SZSE:300522)</td>
<td>35.4%</td>
<td>77.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>22.9%</td>
<td>79%</td>
</tr>
<tr>
<td>Techwing (KOSDAQ:A089030)</td>
<td>18.8%</td>
<td>68%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>上海華測導航技術（深交所：300627）</td>
<td>24.5%</td>
<td>23.4%</td>
</tr>
<tr>
<td>富林精密（深交所：300432）</td>
<td>13.6%</td>
<td>44.2%</td>
</tr>
<tr>
<td>KebNi（OM:KEBNI B）</td>
<td>38.3%</td>
<td>67%</td>
</tr>
<tr>
<td>Pharma Mar（BME:PHM）</td>
<td>11.8%</td>
<td>43.1%</td>
</tr>
<tr>
<td>老普金（港交所：6181）</td>
<td>35.5%</td>
<td>40.6%</td>
</tr>
<tr>
<td>浙江零跑科技（港交所：9863）</td>
<td>15.6%</td>
<td>60.1%</td>
</tr>
<tr>
<td>Vuno（KOSDAQ:A338220）</td>
<td>15.6%</td>
<td>109.8%</td>
</tr>
<tr>
<td>蘇州三門科技（深交所：300522）</td>
<td>35.4%</td>
<td>77.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories（OB:ELABS）</td>
<td>22.9%</td>
<td>79%</td>
</tr>
<tr>
<td>Techwing（KOSDAQ:A089030）</td>
<td>18.8%</td>
<td>68%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 840 stocks from our Fast Growing Global Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們內部持股比例高的 840 只快速成長全球公司的完整名單。</p>
</div><p>Below we spotlight a couple of our favorites from our exclusive screener.</p>
<div class="lb-trans"><p>在這裏，我們重點介紹我們獨家篩選器中的幾家最愛。</p>
</div><h2>3Peak (SHSE:688536)</h2>
<div class="lb-trans"><h2>3Peak（上交所：688536）</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> 3Peak Incorporated focuses on the research, development, and sale of analog integrated circuit products both in China and internationally, with a market cap of CN¥19.06 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 3Peak Incorporated 專注於模擬集成電路產品的研發和銷售，業務覆蓋中國及國際市場，市值為 190.6 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates revenue of CN¥1.44 billion from its operations in the integrated circuit industry.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司在集成電路行業的運營收入為 14.4 億人民幣。</p>
</div><p><strong>Insider Ownership:</strong> 14.2%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 14.2%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 26.6% p.a.</p>
<div class="lb-trans"><p><strong>收入增長預測：</strong> 年均 26.6%。</p>
</div><p>3Peak's revenue is projected to grow significantly at 26.6% annually, outpacing the Chinese market's average growth rate. The company recently reported a turnaround with a net income of CNY 15.56 million for Q1 2025, compared to a loss the previous year. Despite high volatility in its share price and low forecasted return on equity, it's expected to achieve profitability within three years, reflecting strong growth potential amid stable insider ownership dynamics.</p>
<div class="lb-trans"><p>3Peak 的收入預計將顯著增長，年均增長 26.6%，超過中國市場的平均增長率。公司最近報告了扭虧為盈，2025 年第一季度淨收入為 1556 萬人民幣，而去年則出現虧損。儘管其股價波動性較高，且預計股本回報率較低，但預計將在三年內實現盈利，反映出在穩定的內部持股動態下強勁的增長潛力。</p>
</div><ul>
<li>Get an in-depth perspective on 3Peak's performance by reading our analyst estimates report here.</li>
<li>Our valuation report unveils the possibility 3Peak's shares may be trading at a premium.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過閲讀我們的分析師估計報告，深入瞭解 3Peak 的表現。</li>
<li>我們的估值報告揭示了 3Peak 的股票可能以溢價交易的可能性。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4f33f209-075c-4e96-ac20-46f7ba1204f6/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/4f33f209-075c-4e96-ac20-46f7ba1204f6/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688536 Earnings and Revenue Growth as at Jun 2025</p>
<div class="lb-trans"><p>上交所：688536 截至 2025 年 6 月的收益和收入增長</p>
</div><h2>Qi An Xin Technology Group (SHSE:688561)</h2>
<div class="lb-trans"><h2>奇安信科技集團（上交所：688561）</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Qi An Xin Technology Group Inc. is a cybersecurity company offering products and services to government, enterprises, and other institutions in China and internationally, with a market cap of CN¥20.58 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 奇安信科技集團有限公司是一家網絡安全公司，向中國及國際的政府、企業和其他機構提供產品和服務，市值為 205.8 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates revenue from the Information Security Industry segment, amounting to CN¥4.33 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司在信息安全行業的收入為 43.3 億人民幣。</p>
</div><p><strong>Insider Ownership:</strong> 22%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 22%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 19.3% p.a.</p>
<div class="lb-trans"><p><strong>收入增長預測：</strong> 年均 19.3%。</p>
</div><p>Qi An Xin Technology Group is poised for growth with revenue expected to increase at 19.3% annually, surpassing the Chinese market's average. Despite a net loss of CNY 417.68 million in Q1 2025, the company is forecasted to become profitable within three years, indicating robust growth potential. It trades at a significant discount to its estimated fair value and recently announced a CNY 300 million private placement, pending shareholder approval, suggesting strategic financial maneuvers amidst stable insider ownership.</p>
<div class="lb-trans"><p>奇安信科技集團有望實現增長，預計收入年均增長 19.3%，超過中國市場的平均水平。儘管 2025 年第一季度淨虧損為 4.1768 億人民幣，但預計公司將在三年內實現盈利，顯示出強勁的增長潛力。其股票以顯著折扣交易於估計公允價值，並且最近宣佈了一項 3 億人民幣的私募配售，待股東批准，這表明在穩定的內部持股下進行戰略財務操作。</p>
</div><ul>
<li>Click here to discover the nuances of Qi An Xin Technology Group with our detailed analytical future growth report.</li>
<li>In light of our recent valuation report, it seems possible that Qi An Xin Technology Group is trading behind its estimated value.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏瞭解奇安信科技集團的細微差別，查看我們的詳細分析未來增長報告。</li>
<li>根據我們最近的估值報告，奇安信科技集團的股票似乎低於其估計價值。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aabf5e41-e45f-4e0e-b547-15bab0c91da9/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/aabf5e41-e45f-4e0e-b547-15bab0c91da9/chart/ownership-breakdown"/></p>
<p>SHSE:688561 Ownership Breakdown as at Jun 2025</p>
<div class="lb-trans"><p>上交所：688561 截至 2025 年 6 月的持股結構</p>
</div><h2>Zhejiang Jolly PharmaceuticalLTD (SZSE:300181)</h2>
<div class="lb-trans"><h2>浙江佐力藥業（深交所：300181）</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Zhejiang Jolly Pharmaceutical Co., LTD is involved in the research, production, and marketing of Chinese medicinal products both domestically and internationally, with a market cap of CN¥11.11 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 浙江佐力藥業有限公司從事中藥產品的研發、生產和營銷，業務覆蓋國內外，市值為 111.1 億人民幣。</p>
</div><p><strong>Operations:</strong> Zhejiang Jolly Pharmaceutical Co., LTD generates its revenue primarily through the research, production, and marketing of Chinese medicinal products in both domestic and international markets.</p>
<div class="lb-trans"><p><strong>運營：</strong> 浙江佐力藥業有限公司主要通過中藥產品的研發、生產和營銷在國內外市場產生收入。</p>
</div><p><strong>Insider Ownership:</strong> 23.1%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 23.1%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 20.4% p.a.</p>
<div class="lb-trans"><p><strong>收入增長預測：</strong> 年均 20.4%。</p>
</div><p>Zhejiang Jolly Pharmaceutical shows promising growth with revenue expected to rise 20.4% annually, outpacing the Chinese market. Despite a dividend yield of 3.38% not fully covered by free cash flows, the company trades at a good value compared to peers and is priced significantly below its estimated fair value. Recent earnings reports indicate strong financial performance with increased sales and net income year-over-year, while insider ownership remains stable without substantial recent trading activity.</p>
<div class="lb-trans"><p>浙江佐力藥業顯示出良好的增長前景，預計收入年均增長 20.4%，超過中國市場。儘管其 3.38% 的股息收益率未完全由自由現金流覆蓋，但與同行相比，該公司以良好的價值交易，且價格顯著低於其估計公允價值。最近的財報顯示出強勁的財務表現，銷售和淨收入同比增長，而內部持股保持穩定，近期沒有重大交易活動。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Zhejiang Jolly PharmaceuticalLTD's earnings growth report.</li>
<li>The analysis detailed in our Zhejiang Jolly PharmaceuticalLTD valuation report hints at an deflated share price compared to its estimated value.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊以探索我們在浙江佐力藥業收益增長報告中的詳細發現。</li>
<li>我們的浙江佐力藥業估值報告中的分析暗示其股價相較於估計價值被低估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/622eb9bb-56e4-4333-9ef3-063c670c87d3/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/622eb9bb-56e4-4333-9ef3-063c670c87d3/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:300181 Earnings and Revenue Growth as at Jun 2025</p>
<div class="lb-trans"><p>深交所：300181 截至 2025 年 6 月的收益和收入增長</p>
</div><h2>Where To Now?</h2>
<div class="lb-trans"><h2>接下來該如何？</h2>
</div><ul>
<li>Click here to access our complete index of 840 Fast Growing Global Companies With High Insider Ownership.</li>
<li>Seeking Other Investments? Uncover 19 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們 840 家快速成長全球公司內部持股比例高的完整索引。</li>
<li>尋找其他投資？發現 19 家在 COVID 後生存並蓬勃發展的公司，具備應對特朗普關税的正確條件。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不意圖提供財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有引用的預測收入和盈利增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
</div>

由內部人士持股的成長型公司在 2025 年 6 月引領全球市場